Form 8-K - Current report:
SEC Accession No. 0001193125-23-139057
Filing Date
2023-05-09
Accepted
2023-05-09 09:15:52
Documents
15
Period of Report
2023-05-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d420303d8k.htm   iXBRL 8-K 33866
2 EX-99.1 d420303dex991.htm EX-99.1 24143
6 GRAPHIC g420303g0509030323309.jpg GRAPHIC 3867
7 GRAPHIC g420303g0509030323552.jpg GRAPHIC 3627
  Complete submission text file 0001193125-23-139057.txt   203075

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20230508.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20230508_lab.xml EX-101.LAB 17977
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20230508_pre.xml EX-101.PRE 11253
9 EXTRACTED XBRL INSTANCE DOCUMENT d420303d8k_htm.xml XML 3351
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 23900265
SIC: 2836 Biological Products, (No Diagnostic Substances)